Abstract 5071: Minimal Residual Disease (MRD) Status by Peripheral Blood Mononuclear Cells (pbmcs) and Circulating Tumor DNA (ctdna) Demonstrates Rapid, Deep, and Sustained Response in Patients (pts) with Relapsed/refractory Follicular Lymphoma (R/R FL) Treated with Subcutaneous (SC) Epcoritamab Monotherapy in the Pivotal Phase 1/2 EPCORE™ NHL-1 Trial